24 completed, 4 not yet recruiting, 4 recruiting, 3 active not recruiting. 14 Phase 3, 9 Phase 2, 7 Phase 1, 4 Phase 4, 1 Not applicable.
Follow Moderate to Severe Plaque Psoriasis: new trials by email Literature Review of Moderate to Severe Plaque Psoriasis trials Research Report on Moderate to Severe Plaque Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis HS-20118, Placebo - Moderate to Severe Plaque Psoriasis | Phase 2 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 120 | 2026-08-06 | 2026-08-14 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis Drug:WD-890, Drug: placebo - Moderate to Severe Plaque Psoriasis | Phase 3 | Recruiting | Zhejiang Wenda Pharma Technology LTD. | 375 | 2026-03-18 | 2026-06-29 |
| A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis CMS-D001 50mg, CMS-D001 100mg, Placebo - Moderate to Severe Plaque Psoriasis | Phase 2 / Phase 3 | Not yet recruiting | Dermavon Holdings Limited | 540 | 2026-03-03 | 2026-02-25 |
| A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) Bimekizumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis | Phase 1 | Recruiting | UCB Biopharma SRL | 20 | 2025-11-05 | 2026-09-18 |
| A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis Tyk2 inhibitor, Placebo - Plaque Psoriasis, Moderate to Severe Plaque Psoriasis | Not applicable | Recruiting | Usynova Pharmaceuticals Ltd. | 140 | 2025-10-21 | 2025-11-18 |
| A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis SYHX1901 - Moderate to Severe Plaque Psoriasis | Phase 3 | Not yet recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 500 | 2025-06-01 | 2025-04-30 |
| A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis SHR-1139 Injection, SHR-1139 Injection Placebo - Moderate to Severe Plaque Psoriasis | Phase 2 | Active not recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 145 | 2025-03-28 | 2025-07-14 |
| Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis Drug group:vunakizumab (IL-17A inhibitor) - Moderate to Severe Plaque Psoriasis | Recruiting | First Hospital of China Medical University | 1516 | 2025-02-17 | 2025-05-14 | |
| Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis Vunakizumab (IL-17A inhibitor) - Moderate to Severe Plaque Psoriasis | Phase 4 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 1564 | 2025-02-01 | 2025-01-16 |
| A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis bimekizumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis | Phase 3 | Active not recruiting | UCB Biopharma SRL | 89 | 2024-07-29 | 2026-07-17 |
| A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis SHR-1139 Injections, SHR-1139 Injections Placebo - Moderate to Severe Plaque Psoriasis | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 64 | 2024-06-26 | 2026-01-28 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis bimekizumab, ustekinumab, placebo - Moderate to Severe Plaque Psoriasis | Phase 3 | Active not recruiting | UCB Biopharma SRL | 176 | 2024-06-25 | 2026-09-18 |
| Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis ICP-488 Tablets, ICP-488 Placebo - Moderate to Severe Plaque Psoriasis | Phase 2 | Completed | Beijing InnoCare Pharma Tech Co., Ltd. | 129 | 2024-01-04 | 2025-02-28 |
| Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis TLL018 tablets - Moderate to Severe Plaque Psoriasis | Phase 1 | Completed | Hangzhou Highlightll Pharmaceutical Co., Ltd | 73 | 2022-06-10 | 2023-09-22 |
| 2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis secukinumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis | Completed | Novartis Pharmaceuticals | 127 | 2022-03-25 | 2026-10-23 | |
| Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis CT303 - Moderate to Severe Plaque Psoriasis | Phase 1 | Unknown | GC Cell Corporation | 24 | 2021-10-25 | 2022-03-18 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis bimekizumab, Placebo - Moderate to Severe Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 47 | 2021-09-27 | 2025-03-18 |
| Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis NDI-034858 study drug, Placebo - Moderate to Severe Plaque Psoriasis | Phase 2 | Completed | Takeda | 259 | 2021-08-11 | 2023-09-28 |
| A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis Stelara® (Ustekinumab), SB17 (Proposed Ustekinumab Biosimilar) - Psoriasis, Moderate to Severe Plaque Psoriasis | Phase 3 | Completed | Samsung Bioepis Co., Ltd. | 503 | 2021-07-06 | 2025-05-25 |
| A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis bimekizumab - Moderate to Severe Plaque Psoriasis | Phase 2 | Completed | UCB Biopharma SRL | 41 | 2021-04-06 | 2026-08-03 |
Showing 20 of 41. Sign in to see all of them.
Psoriasis (9) · Arthritis, Psoriatic (3) · Axial Spondyloarthritis (1) · Hidradenitis Suppurativa (1) · Non-Radiographic Axial Spondyloarthritis (1) · Spondylitis, Ankylosing (1)
Skin Diseases (12) · Skin Diseases, Papulosquamous (12) · Skin and Connective Tissue Diseases (12) · Arthritis (3) · Bone Diseases (3) · Joint Diseases (3) · Musculoskeletal Diseases (3) · Psoriasis (3) · Spinal Diseases (3) · Spondylarthritis (3) · Spondylarthropathies (3) · Spondylitis (3) · Ankylosis (2) · Axial Spondyloarthritis (1) · Bacterial Infections (1)
bimekizumab (6) · Adalimumab (3) · Ustekinumab (3) · briakinumab (3) · brodalumab (3) · secukinumab (2) · Etanercept (1) · Injections (1) · Midazolam (1) · Sodium Chloride (1) · Tablets (1)
AbbVie (prior sponsor, Abbott) (6) · UCB Biopharma SRL (6) · Guangdong Hengrui Pharmaceutical Co., Ltd (2) · Kyowa Kirin Co., Ltd. (2) · Novartis Pharmaceuticals (2) · AbbVie (1) · Abbott (1) · Bausch Health Americas, Inc. (1) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Biocad (1) · CSPC Ouyi Pharmaceutical Co., Ltd. (1) · Dermavon Holdings Limited (1) · Diamant Thaci (1) · First Hospital of China Medical University (1) · Fresenius Kabi SwissBioSim GmbH (1)
United States (14) · China (11) · Germany (9) · Canada (8) · Poland (8) · Hungary (6) · Czechia (5) · South Korea (5) · Estonia (4) · Russia (4) · Spain (4) · France (3) · Australia (2) · Austria (2) · Belgium (2)
Martin Kaul, MD (2) · David A Williams, MD (1) · Diamant Thaci, Prof. (1) · Jaka Brumen (1) · Martin Okun, MD (1) · Robert D Arbeit, MD (1) · Roman Ivanov, PhD (1) · Seongjin Jo (1)
PMID 21574984, PMID 26138406, PMID 26422722, PMID 26547109, PMID 30328108, PMID 30471012, PMID 32207067, PMID 33891379, PMID 34060012, PMID 34606048, PMID 35544084, PMID 36689515, PMID 36751950, PMID 37950894, PMID 39167366, PMID 39264399, PMID 39328126, PMID 39578348, PMID 40286813, PMID 40886218, PMID 41060492, PMID 41359217, PMID 41580158, PMID 41800601, PMID 42143206
2023 (3), 2016 (2), 2015 (1)